Trastuzumab beyond Progression in Advanced Breast Cancer: National Guidance versus Oncologist's Decision | Citedby Results | Oncology | Karger Publishers

Skip to Main Content

Skip Nav Destination

Trastuzumab beyond Progression in Advanced Breast Cancer: National Guidance versus Oncologist's Decision

Oncology (2014) 86 (1): 22–23.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients

Ju Won Kim
Ah Reum Lim
Ji Young You
Jung Hyun Lee
Sung Eun Song
Nam Kwon Lee
Seung Pil Jung
Kyu Ran Cho
Cheol Yong Kim
Kyong Hwa Park

Cancer Research and Treatment (2023) 55 (2): 531.

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

Tamas Hickish
Ajay Mehta
Mei-Ching Liu
Chiun-Sheng Huang
Rajendra Singh Arora
Yuan-Ching Chang
Youngsen Yang
Vladimir Vladimirov
Minish Jain
Janice Tsang
Karine Pemberton
Behbood Sadrolhefazi
Xidong Jin
Ling-Ming Tseng

Breast Cancer Research and Treatment (2022) 192 (3): 593.